ANI Pharmaceuticals Inc.
ANIP | NASDAQ
$77.48
-$1.37 (-1.74%)
Sep 22, 2026, 11:07 AM ET · Market open
Company Profile
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products. It also manufactures oral solid dose products, semi-solids, liquids, topicals, controlled substances, and potent products. The company serves its products to national wholesalers, specialty pharmacies, retail pharmacy chains, distributors, mail order houses, group purchasing organizations, and hospitals and healthcare providers. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.
Key Executives
| Name | Position |
|---|---|
| Nikhil Lalwani | President, Chief Executive Officer & Director |
| Stephen Carey | Senior Vice President of Finance & Chief Financial Officer |
| Chad Gassert | Senior Vice President of Corporate Development & Strategy |
| Christopher K. Mutz | Senior Vice President & Head of Rare Disease |
| Elizabeth Powell | Chief Compliance Officer & Head of Legal of Rare Disease |
| Irina Rivkind Koffler | Vice President of Investor Relations |
| Krista L. Davis | Senior Vice President & Chief Human Resources Officer |
| Mary Pao | Chief Medical Officer |
| Meredith W. Cook | Senior Vice President, General Counsel & Corporate Secretary |
| Muthusamy Shanmugam | Head of R&D and COO of New Jersey Operations |
| Ori Gutwerg | Senior Vice President of Generics |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 01, 2026 | 4 | Filing |
| Aug 27, 2026 | 4 | Filing |
| Aug 27, 2026 | 3 | Filing |
| Aug 26, 2026 | 4 | Filing |
| Aug 24, 2026 | 8-K | Current Report |
| Aug 13, 2026 | 4 | Filing |
| Aug 11, 2026 | 4 | Filing |
| Aug 07, 2026 | 10-Q | Quarterly Report |
| Aug 07, 2026 | 8-K | Current Report |
| Jul 30, 2026 | 4 | Filing |
ANI Pharmaceuticals Inc.
| Country | United States |
| IPO Date | May 4, 2000 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 970 |
| CEO | Nikhil Lalwani |
Contact Details
210 Main Street West Baudette,
Minnesota 56623 United States
Stock Details
| Ticker Symbol | ANIP |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001023024 |
| CUSIP Number | 00182C103 |
| ISIN Number | US00182C1036 |
| SIC Code | 2834 |
Recent News
- 8 days ago / seekingalpha.comANI Pharmaceuticals, Inc. (ANIP) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
- 29 days ago / globenewswire.comANI Pharmaceuticals Appoints Henry Gosebruch to Board of Directors
- 1 month ago / defenseworld.netAurora Investment Counsel Takes Position in ANI Pharmaceuticals, Inc. $ANIP
- 1 month ago / zacks.comANIP's Cortrophin Guidance Cut Raises the Bar for Second-Half Growth
- 1 month ago / zacks.comShould You Buy ANIP as Low Valuation Meets Cortrophin Execution Risk?
- 1 month ago / zacks.comANIP Tops Q2 Earnings, Stock Down on Cortrophin Sales View Cut
- 2 months ago / seekingalpha.comANI Pharmaceuticals, Inc. (ANIP) Q2 2026 Earnings Call Transcript
- 2 months ago / zacks.comCompared to Estimates, ANI (ANIP) Q2 Earnings: A Look at Key Metrics
- 2 months ago / marketbeat.comANI Pharmaceuticals Q2 Earnings Call Highlights
- 2 months ago / zacks.comANI Pharmaceuticals (ANIP) Q2 Earnings and Revenues Beat Estimates
Add to Watchlist
Select watchlists to add or remove ANIP